Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02955355
Other study ID # 161505
Secondary ID 2016-000374-37
Status Completed
Phase Phase 3
First received
Last updated
Start date December 12, 2016
Est. completion date July 4, 2023

Study information

Verified date July 2023
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) who have completed study 161403 will be able to take part in this study. The main aim of the study is to evaluate side effects in the long-term treatment with HYQVIA/HyQvia. All participants will receive HYQVIA/HyQvia in the same way as they were receiving in study 161403. The dosing interval of HYQVIA/HyQvia can be adjusted after 12 weeks of treatment in study 161505 if the study doctor determines that it is safe to do so. Participants will visit the clinic within 1 week after the first and second dose of HYQVIA/HyQvia and then every 12 weeks for the duration of the study.


Recruitment information / eligibility

Status Completed
Enrollment 85
Est. completion date July 4, 2023
Est. primary completion date July 4, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Has completed Epoch 1 of Study 161403 without CIDP worsening. 2. If female of childbearing potential, the participant must have a negative pregnancy test at baseline and agree to employ adequate birth control measures (eg, birth control pills/patches, intrauterine device, or diaphragm or condom [for male partner] with spermicidal jelly or foam) throughout the course of the study. Exclusion Criteria: 1. Participant has a serious medical condition such that the participant's safety or medical care would be impacted by participation in this Extension Study. 2. New medical condition that developed during participation in study 161403 that, in the judgment of the investigator, could increase risk to the participant or interfere with the evaluation of investigational medicinal product (IMP) and/or conduct of the study. 3. Participant is scheduled to participate in another non-Baxalta clinical study involving an IP or investigational device during the course of this study. 4. The participant is nursing or intends to begin nursing during the course of the study 5. Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study (with the exception of study 161403) involving an IP or investigational device during the course of this study. 6. The participant is a family member or employee of the investigator.

Study Design


Related Conditions & MeSH terms

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Polyradiculoneuropathy
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Intervention

Biological:
HYQVIA
Participants will receive subcutaneous (SC) HYQVIA/HyQvia which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).

Locations

Country Name City State
Argentina Hosp.Britanico de Buenos Aires Ciudad Autonoma Buenos Aires
Brazil Instituto de Neurologia de Curitiba - Hospital Ecoville Curitiba Paraná
Canada University of Alberta Hospital Edmonton Alberta
Canada LHSC - University Hospital London Ontario
Canada Toronto General Hospital, University Health Network Toronto Ontario
Colombia Institucion Prestadora de Servicios de Salud de la Universidad de Antioquia "IPS UNIVERSITARIA" Medellin
Czechia Fakultni nemocnice Ostrava Ostrava Poruba
Czechia Fakultni nemocnice v Motole Prague 5
Denmark Århus Universitetshospital Aarhus C
France Groupe Hospitalier Pellegrin - Hôpital Pellegrin Bordeaux Cedex Gironde
France Hopital Neurologique Pierre Wertheimer Bron Cedex Rhone
France CHU de Nice Nice Alpes Maritimes
Germany Universitaetsklinikum Leipzig AoeR Leipzig Sachsen
Greece University Hospital of Patra Patras
Italy Azienda Ospedaliero Universitaria San Martino Genova
Italy Azienda Ospedaliera Universitaria Policlinico G. Martino Messina
Italy Fondazione Istituto Neurologico Casimiro Mondino Pavia
Italy Azienda Ospedaliero Universitaria Pisana Pisa
Italy Azienda Ospedaliero-Universitaria Santa Maria della Misericordia Udine
Mexico Instituto Nacional de Ciencias Médicas y Nutricion Dr. Salvador Zubiran Mexico Distrito Federal
Poland Uniwersyteckie Centrum Kliniczne Gdansk
Poland Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Lódz
Poland Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie Lublin
Serbia Clinical Center of Serbia Belgrade
Serbia Military Medical Academy Belgrade
Serbia Clinical Center Nis Nis
Slovakia Fakultna nemocnica Nitra Nitra
Spain Hospital Universitari Vall d'Hebron Barcelona
Turkey Pamukkale Uni. Med. Fac. Denizli
Turkey Dokuz Eylul University Faculty of Medicine Izmir
Turkey Selcuk Universitesi Selcuklu Tip Fakultesi Hastanesi Konya
Turkey Celal Bayar University Medical Faculty Manisa
United Kingdom The Walton Centre Liverpool Merseyside
United Kingdom King's College Hospital London Greater London
United States Arizona Neuromuscular Research Center Phoenix Arizona

Sponsors (2)

Lead Sponsor Collaborator
Baxalta now part of Shire Takeda Development Center Americas, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  Canada,  Colombia,  Czechia,  Denmark,  France,  Germany,  Greece,  Italy,  Mexico,  Poland,  Serbia,  Slovakia,  Spain,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Experiencing any Treatment-Emergent Serious Adverse Events (SAEs) and/or Adverse Events (AEs), Regardless of Causality Number of participants experiencing any treatment-emergent SAEs and/or AEs, regardless of causality will be assessed. An AE is defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) is defined as an untoward medical occurrence that at any dose meets one or more of the following criteria: outcome is fatal/results in death, is life-threatening, requires inpatient hospitalization or results in prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event. Throughout the study period of approximately 7 years
Primary Number of Participants Experiencing Causally Related Serious Adverse Events (SAEs) and/or Adverse Events (AEs) Number of participants experiencing causally related SAEs and/or AEs will be assessed. Throughout the study period of approximately 7 years
Primary Number of Participants with Serious and/or Non-Serious Adverse Reactions (ARs) plus Suspected Adverse Reactions (ARs) Number of participants with serious and/or non-serious ARs plus suspected ARs will be assessed. An AR plus suspected AR is any AE that meets any of the following criteria: an AE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or an AE that begins during infusion of IP or within 72 hours following the end of IP infusion, or an AE for which causality assessment is missing or indeterminate. Throughout the study period of approximately 7 years
Primary Rate of Adverse Events (AEs) that may be a Result of Immune-Mediated Responses Rate of AEs that may be a result of immune-mediated response to either immunoglobulin, rHuPH20, or other factors such as allergic reactions, immune complex mediated reactions -local, Immune complex mediated reactions-systemic which will be expressed as the number of events per infusion and per participant-year will be assessed. Throughout the study period of approximately 7 years
Primary Number of Treatment-Emergent Serious Adverse Events (SAEs) and/or Adverse Events (AEs) Associated with Infusions, Regardless of Causality Causality is a determination of whether there is a reasonable possibility that the IP is etiologically related to/associated with the AE. Number of treatment-emergent serious adverse events (SAEs) and/or adverse events (AEs) associated with infusions, regardless of causality will be assessed. Throughout the study period of approximately 7 years
Primary Number of Causally Related Serious Adverse Events (SAEs) and/or Adverse Events (AEs) Associated with Infusions Number of causally related serious adverse events (SAEs) and/or adverse events (AEs) associated with infusions will be assessed. Throughout the study period of approximately 7 years
Primary Number of Adverse Events (AEs) Temporally Associated with Infusions Number of AEs temporally associated with infusions defined as AEs occurring during or within 72 hours after completion of an infusion will be assessed. During or within 72 hours after completion of an infusion
Primary Number of Serious and/or Non-Serious Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Associated with Infusions Number of serious and/or non-serious ARs plus suspected ARs associated with infusions will be assessed. Throughout the study period of approximately 7 years
Primary Number of Infusions Associated with One or More Systemic Adverse Events (AEs) Number of infusions associated with 1 or more systemic AEs will be assessed. Throughout the study period of approximately 7 years
Primary Number of Infusions Associated with One or More Local Infusion Site Reactions Number of infusions associated with 1 or more local infusion site reactions will be assessed. Throughout the study period of approximately 7 years
Primary Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion was Interrupted or Stopped due to Intolerability and/or Adverse Events (AEs) Number of infusions for which the infusion rate was reduced and/or the infusion was interrupted or stopped due to intolerability and/or AEs will be assessed. Throughout the study period of approximately 7 years
Primary Rates of Systemic and local Adverse Events (AEs), Regardless of Causality Rates of systemic and local AEs, regardless of causality will be expressed as number of events per infusion, per participant, and per participant-year. Throughout the study period of approximately 7 years
Primary Rates of Causally Related Systemic and Local Adverse Events (AEs) Rates of causally related systemic and local AEs, will be expressed as number of events per infusion, per participant, and per participant-year. Throughout the study period of approximately 7 years
Primary Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected Adverse Reactions (ARs) Rates of systemic and local adverse reactions (ARs) plus suspected ARs, will be expressed as number of events per infusion, per participant, and per participant-year. Throughout the study period of approximately 7 years
Primary Number of Participants with an Adverse Event (AE) that led to Discontinuation from Study Number of participants with an adverse event (AE) that led to discontinuation from study will be assessed. Throughout the study period of approximately 7 years
Primary Number of Moderate or Severe Adverse Events (AEs) that may be a Result of Immune-Mediated Responses Number of moderate or severe adverse events (AEs) that may be a result of immune-mediated responses will be assessed. Throughout the study period of approximately 7 years
Primary Rate per Infusion of Moderate or Severe Adverse Events (AEs) that may be a Result of Immune-Mediated Responses Rate per infusion of moderate or severe adverse events (AEs) that may be a result of immune-mediated responses will be assessed. Throughout the study period of approximately 7 years
Primary Number of Participants Experiencing Treatment-Emergent Local Infusion Site Reactions Number of participants experiencing treatment-emergent local infusion site reactions will be assessed. All local infusion site treatment-emergent AEs will be reported as adverse reactions. Throughout the study period of approximately 7 years
Primary Number of Participants with Treatment-Emergent with Local Tolerability Events Number of participants with treatment-emergent with local tolerability events during the first 8 weeks of open-label extension study 161505 among participants originally randomized to placebo (no ramp up), versus during the 8 week-ramp-up period for participants originally randomized to HYQVIA in double-blind Study 161403 will be assessed. Throughout the study period of approximately 7 years
Primary Number of Participants in whom Infusion Rate was Reduced and/or the Infusion was Interrupted or Stopped due to Intolerability and/or Adverse Events (AEs) Number of participants in whom infusion rate was reduced and/or the infusion was interrupted or stopped due to intolerability and/or AEs will be assessed. Throughout the study period of approximately 7 years
Primary Number of Participants with Local Infusion Reactions, as a Function of Dosing Interval, Infusion Rate per Site, and Infusion Volume per Site Number of participants experiencing local infusion reactions, as a function of dosing interval, infusion rate per site, and infusion volume per site will be assessed. Throughout the study period of approximately 7 years
Primary Number of Participants whose Anti-Hyaluronidase Antibody Titers Rise by Greater Than or Equal (> or =) ( 4 Fold from the Original Baseline Value from Study 161403 Using Combined Data from Both Studies (161403 and 161505) Number of participants whose anti-hyaluronidase antibody titers rise by > or = 4 fold from the original baseline value from study 161403 using combined data from both studies (161403 and 161505) will be assessed. Throughout the study period of approximately 7 years
Primary Incidence of Binding Antibodies to rHuPH20 Incidence of binding antibodies to rHuPH20 will be assessed. Throughout the study period of approximately 7 years
Primary Incidence of Neutralizing Antibodies to rHuPH20 Incidence of neutralizing antibodies to rHuPH20 will be assessed. Throughout the study period of approximately 7 years
Primary Number of Participants with a Decline of Anti-rHuPH20 Antibody Titers to the Antibody Titer Level at Baseline in Study 161403 or Study 161601 and/or to Less than (<)160 at the Study Completion or Early Discontinuation Number of participants with a decline of anti-rHuPH20 antibody titers to the antibody titer level at baseline in Study 161403 or Study 161601 and/or to <160 at the study completion or early discontinuation will be assessed. Throughout the study period of approximately 7 years
Primary Number of Participants who have Greater than (>) 10,000 Titer of Binding Antibodies to rHuPH20: Neutralizing Antibodies and Cross Reactivity with Hyal-1,2 and 4 Number of participants who have >10,000 titer of binding antibodies to rHuPH20: neutralizing antibodies and cross reactivity with Hyal-1,2 and 4 will be assessed. Throughout the study period of approximately 7 years
See also
  Status Clinical Trial Phase
Recruiting NCT04356781 - Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Terminated NCT01225276 - Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Phase 2/Phase 3
Completed NCT02892890 - Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin N/A
Active, not recruiting NCT03584022 - Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial N/A
Terminated NCT02317562 - Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Phase 3
Recruiting NCT06325878 - Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy N/A
Recruiting NCT06290128 - A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work Phase 3
Completed NCT02293460 - Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Phase 3
Completed NCT02017769 - MRI in Diagnosing and Monitoring CIDP N/A
Withdrawn NCT05257733 - Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases (CIDP Echo-nerf)
Completed NCT03967899 - Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Not yet recruiting NCT04978623 - Role of High Frequency Ultrasound in Demyelinating Polyneuropathies
Active, not recruiting NCT02404298 - Transcriptome Analysis of the Peripheral Blood in CIDP N/A
Completed NCT00099489 - Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Phase 2
Completed NCT01625182 - Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Phase 3
Completed NCT02549170 - A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Phase 3
Active, not recruiting NCT04658472 - Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 2
Withdrawn NCT04529291 - InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy N/A